74 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
, but not limited to, communications by email, regular mail, telephone, fax, instant message and social media platforms whether or not in existence at the date
8-K
EX-10.1
aiiwmd3qg3rkxq
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
cldobwvxee7iy9m76xu
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.3
5uae dkd80h
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
a6j8p9k32r5m6d3khkng
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
eemxdj1e
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
4tidbwpao4ku760
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.01
mjvy hj4rf7fqt8lv
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
EX-10.1
5522wjusvsbl9z8s11w
16 Dec 20
Departure of Directors or Certain Officers
5:01pm